You cannot register anymore for this webinar

Advancing Drug Development:
​​​​​​​Overcoming Bioanalytical Challenges of Nanomedicines and Antibody-Drug Conjugates

Developing novel drug delivery systems such as nanomedicines and antibody-drug conjugates (ADCs) has revolutionized the field of drug development. These targeted therapies have the potential to increase efficacy while minimizing toxicity. However, developing and quantifying these complex therapeutics present unique challenges in liquid chromatography – mass spectrometry (LC-MS) bioanalysis. In this webinar, we will discuss the bioanalytical challenges in developing novel drug delivery systems and explore solutions to overcome them.
 
This webinar will provide an in-depth comparison of bioanalytical challenges faced in developing nanomedicines and ADCs. Our expert speakers will discuss the complexities of bioanalysis, including sample preparation, chromatography, and mass spectrometry detection. Attendees will gain a comprehensive understanding of the similarities and differences in bioanalytical methods used to quantify these complex therapeutics.
 
By attending this webinar, attendees will:
  • Gain an understanding of the unique challenges in LC-MS bioanalysis of nanomedicines and ADCs
  • Learn about the analytical methods used to quantify these complex therapeutics
  • Explore the latest strategies for bioanalytical method development and validation
  • Understand the importance of sample extraction based on predefined scope, e.g. free, bound or total drug
  • Acquire best practices for overcoming bioanalytical challenges in the development of nanomedicines and ADCs
Overall, this webinar will provide attendees with valuable insights into the bioanalytical challenges in developing novel drug delivery systems and equip them with the knowledge and tools necessary to overcome these challenges.
​​​​​​​
Presenters

Daniel Wilffert, PhD
Scientist - Project Manager Bioanalysis
Obtained a PhD in bioanalysis of proteins with LC-MS/MS from University of Groningen in 2016 and started his industrial career as scientist at a GLP/GCP-compliant contract research organization with a focus on bioanalysis of biopharmaceuticals including antibody-drug conjugate (ADCs) with LC-MS/MS. He joined Ardena in 2018, initially as research scientist and in 2019 he transitioned into the role of scientist / project manager of Ardena Assen. Daniel brings experience on bioanalysis of biopharmaceuticals and nanomedicines with LC-MS/MS.t Assen


Theo de Boer, PhD
Principal Scientist Bioanalysis
Obtained a PhD in analytical chemistry & toxicology from University of Groningen in 2001 and started his industrial career as senior scientist at a GLP/GCP-compliant contract research organization with a focus on bioanalysis. Theo headed a chromatography group and became Manager Bioanalytical & Scientific Affairs. After ten years, he joined Ardena in 2013, initially as Associate Director LCMS Bioanalysis and in 2019 he transitioned into the role of Scientific Director Mass Spectrometry. In his current role, Theo brings 20+ years of experience bioanalysis.

Duration
60 min.

Share this webinar